4-Antibody AG

About:

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology.

Website: http://www.4-antibody.com/

Top Investors: EQT Life Sciences, Grazia Equity, Advent Venture Partners, BioMedPartners, Mulligan BioCapital

Description:

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

Total Funding Amount:

25.8M CHF

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2002-01-01

Founders:

Number of Employees:

251-500

Last Funding Date:

2007-01-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai